L3VLUP
ProSign in

ICLR · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ICLRLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ICLR
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterICLRLLY
Q3 202012 holders, $3.0bn33 holders, $14.1bn
Q4 202011 holders, $3.1bn29 holders, $17.3bn
Q1 202114 holders, $3.0bn24 holders, $23.0bn
Q2 202121 holders, $4.2bn24 holders, $27.8bn
Q3 202118 holders, $6.7bn31 holders, $29.9bn
Q4 202117 holders, $8.3bn31 holders, $34.7bn
Q1 202217 holders, $5.6bn24 holders, $35.3bn
Q2 202215 holders, $5.0bn33 holders, $42.7bn
Q3 202212 holders, $4.3bn31 holders, $43.4bn
Q4 202216 holders, $4.5bn31 holders, $46.6bn
Q1 202316 holders, $5.3bn33 holders, $44.3bn
Q2 202317 holders, $5.9bn37 holders, $59.6bn
Q3 202316 holders, $6.0bn44 holders, $67.6bn
Q4 202318 holders, $6.6bn45 holders, $73.6bn
Q1 202421 holders, $8.0bn41 holders, $95.3bn
Q2 202424 holders, $7.7bn43 holders, $110bn
Q3 202420 holders, $6.6bn45 holders, $107bn
Q4 202422 holders, $4.4bn46 holders, $93.9bn
Q1 202519 holders, $4.3bn42 holders, $98.4bn
Q2 202526 holders, $4.9bn43 holders, $93.2bn
Q3 202521 holders, $4.9bn39 holders, $86.7bn
Q4 202518 holders, $5.3bn41 holders, $123bn
Q1 202616 holders, $3.8bn39 holders, $106bn
Q2 202615 holders, $6.5bn44 holders, $132bn
ICLR

Icon Pub LTD Co

Holders
18
Reported value
$5.3bn
Buyers
12
Sellers
20

Breadth -8 among 92 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ICLR (4)

ExodusPoint Capital Management LP, Farallon Capital Management LLC, MFS Investment Management, Ruane Cunniff & Goldfarb LP

Only LLY (27)

Acadian Asset Management LLC, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Dodge & Cox, Freestone Grove Partners LP, GAMCO Investors Inc, Jane Street Group LLC, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Squarepoint Ops LLC, Steadfast Capital Management LP, T. Rowe Price Associates Inc, Tudor Investment Corp, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →